Biostage Stock Current Liabilities
| BSTGDelisted Stock | USD 4.20 0.09 2.10% |
Biostage fundamentals help investors to digest information that contributes to Biostage's financial success or failures. It also enables traders to predict the movement of Biostage OTC Stock. The fundamental analysis module provides a way to measure Biostage's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biostage otc stock.
Biostage |
Biostage OTC Stock Current Liabilities Analysis
Biostage's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Biostage Current Liabilities | 654 K |
Most of Biostage's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biostage is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Biostage has a Current Liabilities of 654 K. This is 99.96% lower than that of the Biotechnology sector and 99.88% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.99% higher than that of the company.
Biostage Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostage's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Biostage could also be used in its relative valuation, which is a method of valuing Biostage by comparing valuation metrics of similar companies.Biostage is currently under evaluation in current liabilities category among its peers.
Biostage Fundamentals
| Return On Equity | -4.92 | |||
| Return On Asset | -2.11 | |||
| Current Valuation | 78.64 M | |||
| Shares Outstanding | 11.64 M | |||
| Shares Owned By Insiders | 50.95 % | |||
| Number Of Shares Shorted | 121.66 K | |||
| Price To Earning | (0.16) X | |||
| Price To Book | 28.47 X | |||
| EBITDA | (8.36 M) | |||
| Net Income | (7.98 M) | |||
| Cash And Equivalents | 4.64 M | |||
| Cash Per Share | 0.40 X | |||
| Total Debt | 115 K | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 2.26 X | |||
| Book Value Per Share | (0.16) X | |||
| Cash Flow From Operations | (2.63 M) | |||
| Short Ratio | 3.35 X | |||
| Earnings Per Share | (0.89) X | |||
| Target Price | 3.0 | |||
| Beta | -0.91 | |||
| Market Capitalization | 73.82 M | |||
| Total Asset | 1.87 M | |||
| Retained Earnings | (65.78 M) | |||
| Working Capital | 7.23 M | |||
| Current Asset | 7.88 M | |||
| Current Liabilities | 654 K | |||
| Net Asset | 1.87 M |
About Biostage Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostage's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostage using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostage based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Biostage OTC Stock
If you are still planning to invest in Biostage check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostage's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |